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ABSTRACT
We previously mapped hypertension-related insulin resistance
quantitative trait loci (QTLs) to rat chromosomes 4, 12 and 16 using
adipocytes from F2 crosses between spontaneously hypertensive
(SHR) and Wistar Kyoto (WKY) rats, and subsequently identified
Cd36 as the gene underlying the chromosome 4 locus. The identity of
the chromosome 12 and 16 genes remains unknown. To identify
whole-body phenotypes associated with the chromosome 12 and 16
linkage regions, we generated and characterised new congenic
strains, with WKY donor segments introgressed onto an SHR genetic
background, for the chromosome 12 and 16 linkage regions. We
found a >50% increase in insulin sensitivity in both the chromosome
12 and 16 strains. Blood pressure and left ventricular mass were
reduced in the two congenic strains consistent with the congenic
segments harbouring SHR genes for insulin resistance, hypertension
and cardiac hypertrophy. Integrated genomic analysis, using
physiological and whole-genome sequence data across 42 rat
strains, identified variants within the congenic regions in Upk3bl,
RGD1565131 andAABR06087018.1 that were associated with blood
pressure, cardiac mass and insulin sensitivity. Quantitative trait
transcript analysis across 29 recombinant inbred strains showed
correlation between expression of Hspb1, Zkscan5 and Pdgfrl with
adipocyte volume, systolic blood pressure and cardiac mass,
respectively. Comparative genome analysis showed a marked
enrichment of orthologues for human GWAS-associated genes for
insulin resistancewithin the syntenic regions of both the chromosome
12 and 16 congenic intervals. Our study defines whole-body
phenotypes associated with the SHR chromosome 12 and 16
insulin-resistance QTLs, identifies candidate genes for these SHR
QTLs and finds human orthologues of rat genes in these regions that
associate with related human traits. Further study of these genes in
the congenic strains will lead to robust identification of the underlying
genes and cellular mechanisms.
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INTRODUCTION
High blood pressure and type 2 diabetes affect over 1 billion people
worldwide and the two conditions frequently co-exist (Shaw et al.,
2010; Vos et al., 2015). Although successful blood pressure treatment
can reduce stroke risk by up to 40%, concomitant reductions in
myocardial infarction are less pronounced (15-25%), suggesting a
role of insulin resistance and other metabolic defects in susceptibility
to myocardial infarction (Wright et al., 2015). Large numbers of
loci associated with hypertension and insulin resistance have been
identified through human genome-wide association studies (GWAS).
However, the molecular mechanisms underlying most of these
associations remain elusive, with many residing in non-coding
regions of the genome, having small gene effects and carrying
associations across multiple adjacent genes (Manolio et al., 2009).
Genetic studies in animal models provide important opportunities
for identifying the genes and mechanisms underlying disease traits.
Experimental crosses in rats and mice, including mapping studies
in congenic strains, have been used to identify hundreds of
physiological and pathophysiological quantitative trait loci
(QTLs) for complex traits such as blood pressure, left ventricular
(LV) mass and type 2 diabetes (Aitman et al., 2008). Whilst genes
underlying these QTLs have in some cases been identified and
translated to mice and humans (Aitman et al., 2008; McDermott-
Roe et al., 2011; Nabika et al., 2012; Petretto et al., 2008), the
overwhelming majority of rodent QTL genes remain unidentified.
The spontaneously hypertensive rat (SHR), the most widely
studied model of human essential hypertension, also manifests
insulin resistance and LV hypertrophy – traits that commonly
coexist with human hypertension (DeFronzo, 1988; Ferrannini
et al., 1987; Lusis et al., 2008). Using crosses between SHR
and Wistar Kyoto (WKY) rats, we identified three QTLs on
chromosomes 4, 12 and 16 linked to adipose insulin sensitivity
(Aitman et al., 1997). Further exploration of the chromosome 4
linkage by expression analysis and congenic mapping identified
Cd36 as the major determinant of SHR hypertension and insulin
resistance in this chromosomal region, a result followed by the
demonstration of associations between CD36, hypertension and
related metabolic traits in mice and humans (Aitman et al., 1999;
Corpeleijn et al., 2006; Farook et al., 2012; Love-Gregory et al.,
2008, 2011; Pietka et al., 2014; Wilson et al., 2016).
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chromosomes 12 and 16 by generating and characterising new SHR
congenic lines and testing candidate genes by analysis of gene
expression and in silico comparative genomic analysis across 42 rat
strains, and between rats and humans. We demonstrate strong
linkage between blood pressure, LV mass, in vivo insulin action and
the congenic regions of SHR chromosomes 12 and 16, and show
significant enrichment for genes associated in human GWAS with
insulin action in the regions of the human genome that are syntenic
to these rat congenic regions.
RESULTS
Body mass and energy homeostasis
Body masses across congenic strains were similar, except for SHR.
W16, which, on average, weighed 14 g less than SHR (Table 1).
WKY rats had heavier epididymal and retroperitoneal fat pads
compared with SHR (Table 1). Both SHR.W4 and SHR.W12 had
similar epididymal, but heavier retroperitoneal fat pads than SHR
(Table 1). Differences in expended energy, food intake and activity
were found among the various strains. Compared with SHR, WKY
rats expended less energy diurnally and nocturnally, consumed less
food and had lower activity counts (Fig. 1A-C; Fig. S1A-C). SHR.
W12 energy expenditure and food intake was lower than in SHR
(Fig. 1A,B; Fig S1A,B), while the other congenics had similar
energy expenditure and food intake to SHR. Circulating leptin
levels were similar across strains (SHR, 2.12±0.32 ng ml−1; SHR.
W4, 3.19±0.51 ng ml−1; SHR.W12, 1.72±0.26 ng ml−1; SHR.W16,
1.80±0.40 ng ml−1; WKY, 1.89±0.25 ng ml−1; P>0.05, one-way
ANOVA followed by Fisher’s LSD test).
In vivo insulin sensitivity
We determined insulin-stimulated glucose clearance (KITT) to
assess each strain’s ability to remove blood glucose in response to
insulin (AUCinsulin: SHR, 990±145; SHR.W4, 1144±110; SHR.
W12, 1106±92; SHR.W16, 1078±82; WKY, 1092±89; P>0.05)
(Fig. 2A,B). WKY KITT was 2.04% min
−1 greater than SHR
(Fig. 2B). KITT in the congenic rats was also significantly
augmented: SHR.W4 cleared glucose at 1.50% min−1, SHR.
W12 at 2.27% min−1 and SHR.W16 at 2.25% min−1, faster than
SHR (Fig. 2B).
Hepatic and skeletal muscle triglycerides
The triglyceride content of the liver was not significantly different
across parental and congenic strains, although WKY and SHR.
W16 tended to be lower than SHR, SHR.W4 and SHR.W12 (SHR,
1.22±0.31 mM; SHR.W4, 0.96±0.37 mM; SHR.W12, 0.82±
0.28 mM; SHR.W16, 0.54±0.26 mM; WKY, 0.49±0.23 mM;
P>0.05). We found no significant differences in skeletal muscle
triglyceride content; although SHR.W4 and SHR.W12 tended
towards WKY levels (SHR, 0.37±0.4 mM; SHR.W4, 0.99±
0.39 mM; SHR.W12, 0.86±0.67 mM; SHR.W16, 0.54±0.28 mM;
WKY, 1.18±0.79 mM; P>0.05).
Hypertension and cardiac hypertrophy
We showed previously that hypertension in SHR, linked to
chromosome 4 in recombinant inbred and congenic strains, is, in
part, caused by renal Cd36 deficiency, as a component of the overall
metabolic syndrome abnormalities encoded by SHR Cd36 (Aitman
et al., 1999; Neckar et al., 2012; Pravenec et al., 1999, 2008).
Therefore, we decided to investigate blood pressure (BP) and
cardiac hypertrophy in the chromosome 12 and 16 lines. The SHR
had significantly higher mean BP (182/122 mmHg) than WKY
(129/88 mmHg) (Fig. 3A,B). Both SHR.W12 and SHR.W16 had
significantly lower BP than SHR (172/115 and 172/110 mmHg,
respectively, in SHR.W12 and SHR.W16; Fig. 3A,B).
Relative LV mass in WKY, SHR.W12 and SHR.W16 (mean
values 1.83, 2.02 and 1.90 g kg−1, respectively) was significantly
lower than in SHR (2.21 g kg−1; Fig. 3C). A significant positive
relationship was found between systolic BP and LVmass (r2=0.618,
P<0.0001; Fig. 3D). Relative heart mass was similar across strains
(mean values: SHR, 3.98; SHR.W12, 3.84; SHR.W16, 4.08; WKY,
3.89 g kg−1; all P>0.05).
Heart rate varied between strains, with WKY having a
significantly higher (+16 bpm) and SHR.W12 significantly lower
(−20 bpm) heart rate than SHR (Table 2). Heart rate combined with
systolic blood pressure, the rate pressure product (RPP), was lower
(−147 bpm mmHg) in WKY than SHR (Fig. 3E). Both congenic
strains had reduced RPP that was 89 and 75 bpm mmHg lower than
SHR (Fig. 3E). RPP was highly correlated with LVmass (r2=0.621,
P<0.0001; Fig. 3F).
We used 2-lead ECG to detect alterations in ventricular
polarisation related to cardiac hypertrophy. WKY had significantly
shorter corrected QT interval (QTc-B), QT dispersion (QTD) and ST
interval (ST-I) than SHR (Table 2). SHR.W12 QTc-B (−13 ms),
QTD (−45 ms) and ST-I (−4.4 ms) were all shorter than SHR; ST-I
alone was shorter (−5.8 ms) in SHR.W16 than SHR (P<0.05).
Expression analysis of genes in the chromosome 12 and 16
loci
Thirty-two genes within the chromosome 12 congenic region and
32 genes in the chromosome 16 congenic region were found from
previous expression quantitative trait locus (eQTL) and quantitative
trait transcript (QTT) data (Langley et al., 2013; Morrissey et al.,
2011) to be either cis-eQTLs or to have gene expression that
correlated across the BXH/HXB recombinant inbred strain panel, in
one or more tissues, with hypertension or insulin resistance-related
traits. We selected 14 of these 64 genes that showed a QTT
correlation in adrenal, kidney or left ventricle, related to
hypertension; or showed a QTT correlation in fat, liver or skeletal
muscle related to whole-body glucose homeostasis or tissue-
specific metabolic phenotypes, for differential expression analysis
in the relevant tissue, between the SHR, WKY and the chromosome
12 and 16 congenic strains (data not shown). Four genes – three on
chromosome 12 and one on chromosome 16 – showed differential
Table 1. Rat body and fat pad mass at 16 weeks of age
N Body mass (g) P Epididymal fat pad (g kg−1) P Retroperitoneal fat pad (g kg−1) P
SHR 20 317 (312,321) – 5.17 (4.89,5.45) – 5.21 (4.82,5.60) –
SHR.W4 16 312 (309,315) 0.5 5.00 (4.70,5.30) 0.4 5.83 (5.56,6.10) 0.026
SHR.W12 18 328 (325,331) 0.1 5.40 (5.10,5.70) 0.3 5.92 (5.54,6.30) 0.018
SHR.W16 16 303 (300,306) 0.04 5.21 (4.73,5.69) 0.9 5.07 (4.71,5.43) 0.6
WKY 20 314 (310,318) 0.6 5.81 (5.53,6.09) 0.003 6.89 (6.40,7.38) 6.9×10−6
Values are means (95% CI). P-values compare each strain with SHR.
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expression between SHR andWKY, and in addition showed similar
expression between the relevant congenic strain and WKY,
indicating cis-regulated control of gene expression from within
the congenic segment (Table 3).
Zkscan5 (zinc finger with KRAB and SCAN domains 5), a
transcript inversely correlated with systolic blood pressure in the
kidney, was 1.25-fold lower in abundance in kidney tissue in SHR.
W12 and WKY compared with SHR (Table 3, Table S4). Two
transcripts, adrenal ubiquitin-specific peptidase 42 (Usp42) and
hepatic heat shock protein β1Hspb1 (inversely correlated to adipocyte
volume), were elevated in SHR.W12 andWKY (1.57- and 2.7-fold on
average, respectively) compared with SHR (Table 3, Table S4).
On chromosome 16, platelet-derived growth factor receptor-like
(Pdgfrl), which correlates with ‘delta captopril effects’ in the left
ventricle, was differently expressed in SHR.W16 and WKY
compared with SHR; WKY expression was reduced, whereas in
SHR.W16, expression was increased. However, expression of
Pdgfrl in adipose tissue was more closely matched in SHR.W16 to
WKY (2.4- and 3.3-fold, respectively) than to SHR (Table 3,
Table S4).
Loci on chromosomes 12 and 16 harbour variants related to
insulin resistance, hypertension and hypertrophy
In order to identify deleterious single-nucleotide variants (SNVs)
present in the SHR congenic regions on chromosomes 12 and 16
(and absent in WKY), that were associated with insulin resistance,
hypertension and LV hypertrophy, we used the PLINK tool (Purcell,
2014) to integrate relevant phenotype data with SNV data from 42
rat strains. We located all SNVs together with their PLINK-assigned
P-values (indicating closeness of SNV-to-phenotype relationship),
for those SNVs with P<0.01 (Fig. S2).
Missense variants in the coding regions of 12 genes with
P<1×10−4 were considered most likely to affect the phenotypes
of interest in SHR, causing a predicted deleterious amino acid
substitution (Table 4). SNVs in Dtx2, Upk3b and Upk3bl were
Fig. 1. Indirect calorimetry, activity and food intake. (A) Energy
expenditure, (B) food intake and (C) activity at age 15 weeks in parental SHR
and WKY and congenic strains (n=10-16 rats per strain). Bar and whiskers
show mean±95% CI; *P<0.05, **P<0.005, ***P<0.0001, compared with SHR.
L, light; D, dark.
Fig. 2. In vivo insulin-mediated glucose clearance. (A) Log(glucose)
disappearance 5-30 min after insulin bolus and (B) insulin-stimulated plasma
glucose clearance (KITT) in parental and congenic strains (n=7-10 rats per
strain). Mean±95% CI; *P=0.0008, **P<0.0001, compared with SHR.
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found to be significantly associated with both insulin resistance and
hypertension (Table 4). Five SNVs in genes AABR06087018.1,
Pms2, Zfp866, Gatad2a and Daglb were found to be exclusively
associated with insulin resistance. In addition, two SNVs in genes
RGD1565131 andGrid2ipwere found to be associated with cardiac
hypertrophy (Table 4).
Identification of human GWAS hits within the syntenic
regions of the donor congenic segments
To investigate whether the chromosomal segments of the human
genome that are syntenic to rat chromosome 12 and 16 congenic
regions contain genes identified as human GWAS hits for relevant
cardio-metabolic traits (including hypertension, left ventricular
Fig. 3. Blood pressure, heart and left ventricular mass. (A) Systolic (SBP), (B) diastolic blood pressure (DBP), (C) relative left ventricle (LV) mass, (D) scatter
plot showing relationship between SBP and LV mass across strains, (E) rate pressure product (RPP), (F) scatter plot showing correlation between RPP and LV
weight across strains. *P<0.05, **P<0.005, ***P<0.0001, between SHR and WKY/congenic strains (n=5-9 rats per strain). P>0.05, differences in left ventricle
mass between WKY and congenic strains. Mean±95% CI.
Table 2. Heart rate and 2-lead ECG parameters in congenic and parental strains at 14-15 weeks of age
N HR (b min−1) P QTc-B (ms) P QTc-B D (ms) P ST-I (ms) P
SHR 9 317 (303,331) – 232 (223,240) – 148 (124,172) – 84.5 (82.5,86.5) –
SHR.W12 8 297 (286,309) 0.0001 219 (214,224) 0.041 103 (83,123) 0.014 78.7 (77.3,80.2) <0.05
SHR.W16 6 316 (297,334) 0.8 221 (218,223) 0.07 116 (85,146) 0.1 80.1 (78.7,81.5) 0.014
WKY 7 333 (317,350) 0.006 215 (207,222) 0.024 86 (53,119) 0.009 75.6 (74.0,77.2) 0.014
Values are means (95% CI). P-values compare each strain with SHR.
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hypertrophy, insulin resistance and type 2 diabetes) we mined the
syntenic regions in the human genome for reported GWAS hits
(Table S1).
We identified GWAS hits associated with type 2 diabetes,
metabolic syndrome and insulin resistance-related traits in five
genes in the human synteny regions of the chromosome 12 congenic
strain, and with 10 genes in the synteny regions of the chromosome
16 congenic strain (Table 5, Table S5). This represents a significant
enrichment for GWAS hits in these chromosomal regions
(chromosome 12 synteny regions, P<0.003; chromosome 16
synteny region, P<6.7×10−13; Table 5).
GWAS hits associated with blood pressure were identified in two
genes in the chromosome 12 congenic strain synteny regions and
two genes in the chromosome 16 congenic strain. GWAS hits for LV
mass were not identified in the chromosome 12 synteny regions but
were identified in two genes in the chromosome 16 synteny region,
one of these also being associated with blood pressure. Syntenic
segments of neither region were significantly enriched for genes or
GWAS hits for blood pressure-related traits, but the syntenic regions
of the chromosome 16 region were significantly enriched for GWAS
hit genes for left ventricular (LV) mass (P<8.7×10−4) (Table 5).
Three genes, SLC12A9 (chromosome 12), CACNA1D and CSMD1
(chromosome 16), were associated with both blood pressure and
insulin resistance-related metabolic traits (Table S5).
DISCUSSION
Hypertension and insulin resistance frequently co-occur in the same
individual. Pathologically increased blood pressure leads to increased
myocardial load, while insulin resistance affects myocardial
metabolism and vascular reactivity, leading to compensatory LV
hypertrophy and failure (Evrengul et al., 2005; Kaftan et al., 2006;
Roman and Devereux, 2014).
We previously mapped QTLs on SHR chromosomes 4, 12 and 16
that were associated with reduced insulin-stimulated glucose uptake
in isolated adipocytes from hypertensive SHR compared with
normotensive WKY (Aitman et al., 1997). Subsequent studies
investigating the chromosome 4 region identified Cd36, a fatty acid
translocase, as the gene underlying both insulin sensitivity and blood
pressure QTLs on SHR chromosome 4 (Aitman et al., 1999; Pravenec
et al., 2008). CD36 has since been found to be important in the
development of type 2 diabetes and essential hypertension in humans
(Corpeleijn et al., 2006; Lepretre et al., 2004; Wang et al., 2012).
In this study, we explored regions on SHRchromosomes 12 and 16
and their function in regulating blood pressure, cardiac hypertrophy
and insulin resistance. Cardiovascular and metabolic phenotyping of
the congenic strains showed that the chromosome 12 and 16 congenic
strains had captured important genes for both cardiovascular and
metabolic phenotypes within the congenic segments. Systolic blood
pressure was reduced by around 10 mmHg in both of the congenic
strains, equivalent to ∼20% of the difference between SHR and
WKY. The variation in systolic blood pressure across the SHR,WKY,
and two congenic strains explained over 60% of the variation in both
left ventricular mass and left ventricular load across the four strains
(Fig. 3E,F). The reduction in left ventricular mass and myocardial
load in either of the two congenic strains comparedwith parental SHR
rats was almost equivalent to the total difference between the SHR
and WKY strains. In metabolic terms, insulin tolerance testing
showed an increase in KITT, the glucose disposal rate, by over 50% in
both congenic strains compared with the insulin-resistant SHR
parental strain. As with several of the cardiovascular traits, this
increase in insulin action was similar to the entire difference between
the SHR and WKY parental lines.
We combined physiological, eQTL and differential expression data
to identify candidate genes for SHR insulin resistance and blood
Table 3. Relative transcript levels of candidate cis-regulated eQTL genes residing in the chromosome 12 and 16 congenic regions
Relative transcript level
Gene Chromosome location of eQTL gene Tissue SHR Congenic P WKY P
Zkscan5 12:13,224,021-13,245,216:-1 Kidney 1.01 (1.00,1.01) 0.81 (0.73,0.89) 0.003 0.80 (0.69,0.90) 0.006
Usp42 12:14,904,019-14,922,553:1 Adrenal gland 1.00 (1.00,1.01) 1.54 (1.41,1.66) 0.0004 1.60 (1.19,2.00) 0.029
Hspb1 12:25,837,084-25,838,661:-1 Liver 1.00 (1.00,1.00) 2.53 (1.87,3.20) 0.003 2.79 (2.57,3.00) 2×10−6
Pdgfrl 16:54,098,419 -54,161,461:-1 Adipose 1.03 (1.00,1.06) 2.99 (1.95,4.02) 0.006 2.75 (2.34,3.16) 9×10−5
Left ventricle 1.02 (0.99,1.05) 3.84 (3.03,4.65) 0.001 0.64 (0.47,0.81) 0.01
Values are means (95% CI). P-values compare each strain with SHR. eQTL, expression quantitative trait locus; congenic, refers to the congenic strain of interest:
SHR.W12 for genes on chromosome 12, SHR.W16 for genes on chromosome 16.
Table 4. Single nucleotide variants present in SHR and absent in WKY that were most significantly (P<10−4) linked to insulin resistance,
hypertension and left ventricular hypertrophy
Trait Chr. Position Ref. Var. PLINK P-value Gene Ensembl gene ID Δαα
IR 16 23202666 G A 1.03E−13 AABR06087018.1 ENSRNOG00000049177 A38T
12 25707930 G A 2.13E−08 Dtx2 ENSRNOG00000001432 P249S
12 25680540 C T 2.13E−08 Upk3b ENSRNOG00000023686 R56Q
12 14765423 C T 1.21E−07 Pms2 ENSRNOG00000001040 V207M
12 25659035 C T 5.17E−07 Upk3bl ENSRNOG00000038896 D57N
16 21336324 G A 1.16E−06 Zfp866 ENSRNOG00000042580 E48K
16 21175611 A G 1.16E−06 Gatad2a ENSRNOG00000022173 S235G
12 15170110 C A 1.56E−05 Daglb ENSRNOG00000001079 E398D
HBP 12 25659035 C T 4.92E−06 Upk3bl ENSRNOG00000038896 D57N
12 25680540 C T 3.47E−05 Upk3b ENSRNOG00000023686 R56Q
12 25707930 G A 3.47E−05 Dtx2 ENSRNOG00000001432 P249S
LVH 12 14262304 A G 1.71E−05 RGD1565131 ENSRNOG00000025212 H71R
12 15266170 G A 2.21E−05 Grid2ip ENSRNOG00000030927 P739S
Chr., chromosome; HBP, high blood pressure; IR, insulin resistance; LVH, left ventricular hypertrophy; Ref., reference nucleotide; Var., variant present in SHR;
Δαα, amino acid change consequent to variant.
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pressure encoded on these congenic segments. Of the 64 genes within
the chromosome 12 and 16 congenic intervals that were identified
previously as either cis-eQTL genes in relevant tissues or correlated in
QTT analysis with relevant cardio-metabolic phenotypes, nine genes
on chromosome 12 and five genes on chromosome 16 were tested
because of correlation in QTT, with the most plausible tissue
expressing the differentially expressed gene. Three genes from
chromosome 12 – Hspb1, Zkscan5 and Usp42 – were found to be
differentially expressed between SHR and the congenic strain in the
tissue of interest. Of the proteins encoded by these genes, Hspb1 (also
known as Hsp27) has been the most studied and is involved in
numerous cellular processes, including protection from oxidative
stress (Acunzo et al., 2012; Matsumoto et al., 2015). This metabolic
stress protein has been found to improve insulin signalling when
induced in monocytes extracted from diabetic and obese patients
(Simar et al., 2012). Hsp27 was also upregulated with Pparg and
Hsp72 by the experimental compound naringin, which improves
insulin sensitivity and lipid metabolism in rats (Sharma et al., 2011).
Scant information is available for Zkscan5, although oneGWAS study
located a single nucleotide polymorphism (SNP) with significant
association to dehydroepiandrosterone sulfate levels, which have been
linked to pulmonary hypertension (Ventetuolo et al., 2016; Zhai et al.,
2011). Ubiquitin-specific peptidase 42 (Usp42), stabilises p53 in
response to stress and is a transcriptional regulator; however, there is
currently no study linking the gene to cardio-metabolic traits (Hock
et al., 2014).
Of the five genes on chromosome 16 that were correlated in QTT
with cardio-metabolic phenotypes, only one gene, Pdgfrl, was
found to be differentially expressed between SHR and congenic
strain adipose tissue, showing similarly increased expression in
SHR.W16 and WKY compared with SHR, in epididymal fat.
The PDGF signalling pathway regulates a number of processes,
including angiogenesis, wound healing and inflammation (Hu and
Huang, 2015). Moreover, low levels of PDGF-BB, a component of
this signalling pathway, is linked to cardiovascular events in type 2
diabetics (Yeboah et al., 2007).
From linkage disequilibrium analysis across 42 rat strains, we
found SHRSNVs in 10 genes in the chromosome 12 and 16 congenic
regions that were significantly associated across the 42 rat strains with
hypertension, hypertrophy and insulin resistance in the SHR. Three
genes within the chromosome 12 congenic strain interval (Dtx2,
Upk3b, Upk3bl) contain SNVs that were significantly associated
across 42 rat strains with both hypertension and insulin resistance.
Deltex 2 E3 ubiquitin ligase (Dtx2), acts as a negative regulator of
Notch signals in mature T-cells (Lehar and Bevan, 2006). Inhibition
of Notch signalling has been reported to improve insulin resistance
(Pajvani et al., 2011). Furthermore, Notch2 SNPs have been reported
in a number of GWAS studies associated with cardiovascular disease
and type 2 diabetes (Qi et al., 2013; Zeggini et al., 2008). Therefore, it
is plausible that the SHR variant of Dtx2 has a reduced ability to
negatively regulate Notch signals in relation to downstream insulin
signalling, although this will require testing in future studies.
Uroplakin 3b (Upk3b), is a minor component in the asymmetric
unit membrane of the urothelium (Yu et al., 1994) and Upk3b
expression in the early mouse embryo is reportedly restricted to
mesothelial cells and epicardium (Huang et al., 2012). However,
little is known about the physiological function of Upk3b and no
association with hypertension or insulin action has been reported
Table 5. Contingency tables for type 2 diabetes, insulin resistance, metabolic syndrome, hypertension and left ventricular hypertrophy
Within congenic
region
Outside congenic
region Total P
Type 2 diabetes, insulin resistance,
metabolic syndrome
Chr. 12 Observed GWAS hit genes 5 70 75
Non-GWAS hit genes 510 26104 26614
Total 515 26174 26689
Expected GWAS hit genes 1 74 75
Non-GWAS hit genes 514 26100 26614
Total 515 26174 26689 0.0028
Chr. 16 Observed GWAS hit genes 10 65 75
Non-GWAS hit genes 726 25888 26614
Total 736 25953 26689
Expected GWAS hit genes 2 75 75
Non-GWAS hit genes 734 26614 26614
Total 736 25953 26689 6.7×10−13
Hypertension Chr. 12 Observed GWAS hit genes 2 49 51
Non-GWAS hit genes 513 26125 26638
Total 515 26174 26689
Expected GWAS hit genes 1 50 51
Non-GWAS hit genes 514 26124 26638
Total 515 26174 26689 0.3
Chr. 16 Observed GWAS hit genes 2 49 51
Non-GWAS hit genes 734 25904 26638
Total 736 25953 26689
Expected GWAS hit genes 1 50 51
Non-GWAS hit genes 735 25903 26638
Total 736 25953 26689 0.6
Left ventricular hypertrophy Chr. 16 Observed GWAS hit genes 2 8 10
Non-GWAS hit genes 734 25945 26679
Total 736 25953 26689
Expected GWAS hit genes <1 10 10
Non-GWAS hit genes 735.72 25943 26679
Total 736 25953 26689 8.7×10−4
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hitherto. The related gene Upk3bl has scant published information
regarding its function, but may have involvement in the rare disease
rhabdoid glioblastoma (Koh et al., 2015).
Our human-rat comparative analysis of the chromosome 12 and
16 congenic segments indicated a significant enrichment for insulin
resistance-related GWAS hit genes on the regions syntenic to both
congenic segments, with 5 and 10 GWAS hit genes for these traits
within the syntenic regions to the chromosome 12 and 16 congenic
segments, respectively. We also found an enrichment, although less
significant, for GWAS hit genes for cardiac hypertrophy in the
regions syntenic to the chromosome 16 congenic strain.
Three of the GWAS genes (SLC2A9, CACNA1D and CSMD1),
one in the chromosome 12 and two in the chromosome 16 synteny
groups, harboured SNPs significantly associated with both blood
pressure and insulin resistance/type 2 diabetes in humans. SLC2A9
encodes an electroneutral inorganic cation-chloride co-transporter
whose function has yet to be fully established (Gagnon and Delpire,
2013). CACNA1D encodes a voltage-dependent calcium channel,
and SNPs in this gene are associated by GWAS with insulin
resistance in African Americans, and with blood pressure in Chinese
and people of African ancestry (Irvin et al., 2011; Lu et al., 2015;
Zhu et al., 2015). Deletion of Cacna1d in mice was expected to
affect insulin secretion and result in hyperglycaemia; however, this
was not observed (Platzer et al., 2000). However, the authors did
find that Cacna1d−/−mice were affected by arrhythmia and reduced
heart rate compared with the wild type (Platzer et al., 2000).
CSMD1 encodes the cub and sushi domains 1 protein and, as for
CACNA1D, SNPs in this gene are associated with insulin resistance
in African Americans, and with blood pressure in the Han Chinese
population (He et al., 2013; Irvin et al., 2011). Functionally, Csmd
has been found to negatively regulate the classical complement
pathway (Kraus et al., 2006). Thus, given the growing evidence of
the role of complement in cardiovascular and metabolic disease
(Hertle et al., 2014), this gene may be important in preventing over-
activity of the complement system – a phenomenon observed in
both cardiovascular and metabolic disease.
The glutamate receptor ionotropic delta 1 geneGRID1was one of
two GWAS orthologues for LV hypertrophy in the chromosome 16
congenic region (Vasan et al., 2009). Grid1−/− mice were not
reported to have a cardiovascular phenotype (Gao et al., 2010);
however, deletion ofGRID1 and surrounding genes in humans, was
associated with cardiac defects (van Bon et al., 2011). The second
hypertrophy-related gene neuregulin 3 (NRG3) has unknown
function; however, one study in the rat showed downregulation of
neuregulin receptor signalling in the transition from hypertrophy to
failure in rats (Rohrbach et al., 1999).
Our study provides a complementary view to a recently
published study by Sedova et al. (2016), which carried out blood
pressure and metabolic testing and an appraisal of SNVs on a
single SHR congenic strain for chromosome 16. Although these
two studies highlight some genes in common (such as the plausible
candidates Lpl and Gatad2a), our study, of congenic strains on
chromosomes 12 and 16, was carried out in linkage regions to
adipocyte insulin resistance that we had defined previously.
Sedova carried out a limited appraisal of SNVs between the two
parental strains in the chromosome 16 congenic region. Our study
may have more plausibility, as it drew upon extensive gene
expression and QTT data, as well as linkage disequilibrium data
across 42 rat strains, to filter and select candidate genes within the
congenic regions.
The genes and mechanisms underlying hypertension and insulin
resistance, in humans and rats, are yet to be fully elucidated. Here,
we combined genetic, physiological and comparative genomic
analyses to define chromosomal regions underlying SHR blood
pressure, insulin sensitivity and left ventricular mass, identifying
candidate genes and finding human orthologues of rat genes in these
regions that associate with these traits. Further study of these genes
in the congenic strains will lead to robust identification of the
underlying genes and cellular mechanisms.
MATERIALS AND METHODS
Generation of congenic strains
Congenic lines containing regions of WKY chromosomes 12 and 16 on an
SHR background were constructed with a speed congenic approach using
SHR/NCrl as recipient genome and WKY/NCrl (Charles River
Laboratories, Margate, UK) as donor genome (Markel et al., 1997). A
chromosome 4 congenic line that captured Cd36 was generated for
comparative purposes. Microsatellite marker analysis was carried out at each
backcross (Tables S2 and S3), and progeny heterozygous for relevant
congenic segments with the lowest proportion of WKY background
genotypes were selected as breeders. Once all background microsatellites
were confirmed as homozygous SHR, each of the chromosome 4, 12 and 16
lines were intercrossed. Offspring that were homozygous for WKY in the
congenic interval (using microsatellites in Table S3) were brother-sister
mated to fix the congenic interval. The lines were designated SHR.W4-
(D4rat143-D4rat10)/Tja (SHR.W4), containing a congenic segment of
24.2 Mb; SHR.W12-(D12rat1-D12mit3)/Tja (SHR.W12), containing a
congenic segment of 28.6 Mb; and SHR.W16-(D16rat88-D16rat15)/Tja
(SHR.W16), containing a congenic segment of 79.2 Mb. All animals were
maintained under 12 h:12 h light-dark cycle with free access to food and
water. Experimental procedures were approved by the UK Home Office
under the Animals (Scientific) Procedures Act 1986.
Energy expenditure, food intake and activity
Indirect calorimetry, food intake and activity were assessed using the
Oxymax Lab Animal Monitoring System (CLAMS, Columbus Instruments,
Columbus, OH, USA) for 72 h (24 h acclimatisation; 48 h data collection)
with free access to water and chow. Energy expenditure was calculated
according to McLean and Tobin (CV, calorific value, kcal kg−1 h−1)
(McLean and Tobin, 1987). Serum leptin (n=6 per group) was measured by
ELISA (Millipore, UK).
Whole-body insulin sensitivity
Insulin-stimulated glucose clearance (Actrapid; Novo Nordisk, Bagsvaerd,
Denmark) was measured by glucometer (Contour, Bayer Healthcare, Basel,
Switzerland), in venous blood drawn from the tail vein of overnight-fasted
rats with free access to water, 5-30 min following an intravenous insulin
bolus, according to Eskens et al. (2013), and using an insulin dose,
1 U kg−1, previously used to reliably assess whole-body response to insulin
(Diaz-Castroverde S, 2016; Lambert et al., 2016; Moak et al., 2014). Rats
were anaesthetised throughout in order to reduce stress associated with
hypoglycaemia and this has not been found to affect the interpretation of
insulin sensitivity in the same rat strains (Hulman et al., 1991, 1993). Body
temperature was controlled using the Homeothermic Monitoring System
(Harvard Apparatus). Plasma insulin was determined by ELISA (Rat/Mouse
Insulin ELISA, Millipore). Glucose clearance (KITT, % min−1) was
calculated from the log(glucose) disappearance curve 5-30 min (Fig. 2A)
as 0.693/t1/2×100 (Lundbaek, 1962).
Hepatic and skeletal muscle triglyceride analysis
Lipid was extracted from liver and soleus muscle (n=4 per group) according
to manufacturer’s instructions and analysed using the Triglyceride
Quantification Kit (Abcam, Cambridge, UK).
Blood pressure and ECG telemetry
Blood pressure and 2-lead ECG were measured in conscious, free-moving
14- to 15-week-old male rats. A blood pressure ECG radio-telemetry device
was surgically implanted in accordance with the manufacturer’s instructions
and cardiovascular measurements taken at least 1 week after implantation
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(HD-S11; Data Sciences International, Roermond, The Netherlands). Blood
pressure, heart rate and QT interval were measured for 5 min h−1 over a
consecutive 48 h period, analysed using Ponemah (Ponemah Data Analysis
v5.20, Data Sciences International, Roermond, The Netherlands) and
presented as mean values over this time period. Rate pressure product was
calculated as systolic blood pressure×heart rate×10−2 (Gobel et al., 1978).
Bazett’s correction for QT was calculated as QTc-B=QT/(RR)1/2 (Kmecova
and Klimas, 2010); QTc-B D was calculated as the difference between
maximum and minimum QTc-B (de Bruyne et al., 1998).
Expression and variant analyses of genes in the chromosomes
12 and 16 QTLs
We used two approaches to identify candidate genes for the SHR traits
investigated in this study: first, we used previously generated eQTL (Langley
et al., 2013; Petretto et al., 2006) and quantitative trait transcript (QTT)
(Morrissey et al., 2011) data to identify eQTL genes within the congenic
intervals and genes that correlated with (patho)physiological traits across the
BXH/HXB recombinant inbred strain panel. Relative transcript levels were
quantified by real-time quantitative PCR (qPCR) from cDNA reverse
transcribed from total RNA of 4-5 animals per group (iScript cDNASynthesis
Kit, Bio-Rad) extracted with Tri-reagent (Sigma) from adrenal gland,
epididymal fat, kidney, left ventricle, liver and skeletal muscle. Primers were
designed using Primer-BLAST software (http://www.ncbi.nlm.nih.gov/tools/
primer-blast/) with sequences verified for absence of single nucleotide
polymorphisms using SHR and WKY whole-genome sequences and the
Integrated Genomics Viewer (http://www.broadinstitute.org/igv/). qPCR was
carried out on the 7900HT Fast Real-Time PCR System (Thermo Fisher
Scientific). CT values were analysed using the 2−ΔΔCT method normalising to
β-actin gene, with SHR used to compare strains.
Second, we used PLINK to rank SHR SNVs within the congenic intervals
on chromosome 12 and 16, with the closest relationship to each trait of
interest (insulin resistance, hypertension, hypertrophy), allowing us to
compare deleterious SNVs present in SHR and absent inWKY (Atanur et al.,
2013; Purcell, 2014). We obtained metabolic and cardiovascular data from
the Rat Genome Database on 42 rat strains and grouped strains depending on
glucose and insulin levels, blood pressure, and left ventricular mass (http://
rgd.mcw.edu/wg/phenotype-data13).We then generated .map and .ped input
files for the PLINK program from a .vcf file containing all SNVs of the 42
strains (Hermsen et al., 2015). The original genotype calls were adjusted such
that heterozygous calls were made if >25% and <75% of the reads supported
a non-reference genotype, otherwise they were called as homozygous. The
effects of SNVs on genes, transcripts and protein sequence were evaluated
using a locally installed Ensembl Variant Effect Predictor (VEP) (http://
www.ensembl.org/info/docs/tools/vep/script/index.html).
The VEP analysis was based on rat genome assembly Rn0r_5.0 and
Ensembl release 78 annotations. The PLINK analysis was performed as
standard case/control association analysis. We used the additional PLINK
options ‘–assoc’ and ‘−allow-no-sex’.
Comparative analysis of the congenic intervals with
corresponding regions in the human genome
Using the Virtual Comparative Map (VCMap), we located regions of the
human genome orthologous to the chromosome 12 and 16 congenic
intervals (Kwitek et al., 2001). With the genomic coordinates corresponding
to the congenic intervals, we identified human SNPs associated with ‘non-
insulin-dependent diabetes mellitus’ and ‘susceptibility to essential
hypertension’ using Ensembl’s BioMart (Cunningham et al., 2015). In
addition, we identified SNPs in genes with genome-wide significance
(including those with borderline significance, i.e. P=5×10−7) using the
NHGRI-EBI GWAS catalogue (https://www.ebi.ac.uk/gwas/) connected to
the following search terms: blood pressure, blood pressure (age interaction),
blood pressure (anthropomorphic measures interaction), blood pressure
(smoking interaction), blood pressure measurement (cold pressor test),
blood pressure measurement (high sodium and potassium intervention),
blood pressure measurement (high sodium intervention), blood pressure
measurement (low sodium intervention), blood pressure response to
hydrochlorothiazide in hypertension, blood pressure variability, cardiac
hypertrophy, cardiac muscle measurement, cardiac repolarisation, cardiac
structure and function, cardiovascular disease risk factors, cardiovascular
heart disease in diabetics, diabetes-related insulin traits, diastolic blood
pressure, diastolic blood pressure (alcohol consumption interaction), fasting
glucose-related traits, fasting glucose-related traits (interaction with BMI),
fasting insulin-related traits, fasting insulin-related traits (interaction with
BMI), fasting plasma glucose, heart rate, hypertension, hypertension (young
onset), insulin-related traits, left ventricular mass, QT interval, systolic
blood pressure, systolic blood pressure (alcohol consumption interaction)
and type 2 diabetes.
To test whether the congenic regions were enriched for orthologues to
cardio-metabolic GWAS hits in humans, we used the above GWAS search
results and information gathered from Ensembl, to establish the total number
of genes within and outside the congenic regions.
Statistical analysis
Data were analysed using Minitab 17 (Minitab Ltd, Coventry, UK). All
physiological and qPCR data were analysed by one-way ANOVA followed
by Fisher’s least significant difference test. P-values in the PLINK analysis
were considered significant with a nominal P-value <1×10−4. SNV and
GWAS enrichment analyses were performed by chi-squared analysis.
Values are expressed as mean±95% confidence intervals (CI), with values
of P<0.05 considered significant.
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Figure S1. Indirect calorimetry, activity and food intake during a 48 hour 
period (A), Energy expenditure (Kcal.h-1), (B), food intake (grams) and, (C), 
activity (counts) measured from parental and congenic strains. Mean values 
per hour per rat ±95%CI. Shaded region indicates periods of darkness in the 
12h:12h dark:light cycle. 
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Figure S2. Genomic location of single nucleotide variations associated 
with insulin resistance, hypertension and cardiac hypertrophy within the 
congenic intervals on chromosomes 12 and 16. Individual plots of 
logarithmised p-values against genomic positions within QTL intervals on 
chromosomes 12 and 16, respectively. P-values less than 0.01 were plotted 
for the QTL on chromosome 12 (A,C,D) and for the QTL on chromosome 16 
(B,D,F). Three different phenotypes are shown: insulin resistant versus insulin 
sensitive (A,B), hypertensive versus normotensive strains (C,D) and 
hypertrophic versus non-hypertrophic strains (E,F) Grey circles represent all 
SNVs that are located between individual gene start and end positions. All 
SNVs that are considered to have deleterious consequences are shown as 
red open circles. Deleterious SNVs that are found only in SHR strain but not 
in WKY are plotted as filled red circles. 
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Table S1 Boundaries of rat chromosome 12 and 16 congenic regions 
with their syntenic regions in the human genome 
Rat (Rn_3.4) Human 
(GRCh37.p5) 
12:1-28,615,362 19:7,294,011-8,023,457 
13:27,746,033-33,677,272 
7:97,619,416-99,156,045 
7:6,012,870-6,746,566 
7:300,711-5,659,672 
7:99,613,219-99,812,010 
7:100,026,302-100,318,423 
7:100,782,547-100,882,893 
7:101,256,605-102,199,972 
7:75,368,279-76,090,972 
7:72,716,514-74,203,659 
7:69,063,905-71,877,360 
7:66,108,216-66,452,690 
7:65,419,800-65,579,805 
7:56,019,611-56,160,689 
12:131,510,000-132,195,635 
16:819,225-80,047,126 10:80,828,792-81,205,383 
10:81,852,307-81,914,880 
3:52,434,513-57,743,174 
3:15,247,733-16,347,594 
10:47,000,568-51,026,325 
10:82,049,434-88,809,959 
19:16,284,286-16,771,938 
19:17,186,591-19,774,503 
8:18,081,198-20,103,676 
4:164,047,860-189,068,649 
8:12,612,992-17,913,925 
8:8,175,258-9,639,856 
8:29,190,579-42,263,415 
13:52,951,302-53,024,763 
13:52,585,630-52,706,779 
8:1,656,642-6,666,038 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Disease Models & Mechanisms 10: doi:10.1242/dmm.026716: Supplementary information 
Table S2. Microsatellite markers, primer sets and expected sizes from SHR and 
WKY, for genotyping during generation of congenic strains 
Marker Primer sequence 
Product size 
SHR (bp) WKY (bp) 
D1Rat95 F 5’- ACACAGCTAAGACACGGGCT-3’R 5’- CAAATTACACTCTTGGGGCAA -3’ 186 174 
D1Rat27 184 158 
D1Rat230 
F 5’- GGGCAAGCAAAGTACATGGT-3’
R 5’- TCTCTCCAGCTGCAGGATTT-3’
F 5’- AAAACAAACCTGCTTCAGGG-3’
R 5’- GACTGCAGATGAACAAGCCA-3’ 206 210 
D1Rat51 175 173 
D1Rat74 
F 5’- TTGCCTGAGAGACTGTGCC-3’
R 5’- CCCTCAGTTCAAGAGTAACCTCA-3’
F 5’- CACTTTCAAGATATCCTGTTGCTT-3’
R 5’- CTCAGCAACCCCTAAGAGTG-3’ 196 176 
D1Rat156 163 183 
D2Rat4 182 168 
D2Rat184 
F 5’- ATTCAATAAGCCTGGGGGAC-3’
R 5’- ATGTTGGTGTGCTTCCTGGT-3’
F 5’- ACCAAATGGCCATGACAAAA-3’
R 5’- TACAAGGTCCCTTCTGTGGC-3’
F 5’- CCCAAAGCCAGTCAAGAGTC-3’ 223 231 
D2Rat234 ? 104 
D2Rat138 
R 5’- CTTCACTGACAAACTGCCAAA-3’
F 5’- ATATTCAAGCTGGCTTCCCC-3’
R 5’- GTAGAGCAAGATGGGGTGGA-3’
F 5’- TCCATGCACTTGTACGATGC-3’
R 5’- CCCATAGAACCTAATCTCTGAAGA-3’ 247 233 
D3Rat53 156 176 
D3Rat186 
F 5’- TTGTCTCTGGTTCCAGGTCC-3’
R 5’- GCTGGAAGGTACCTGTGGAA-3’
F 5’- CCTGCATCCTCTTGTGGACT-3’ 143 157 
D3Rat217 
R 5’- TTCCTGTCATTTCATGTTATTGAA-3’
F 5’- TGGCAATAACTCAAGGGCTC-3’ 176 184 
D4Rat233 
R 5’- AGCCAAATAGGTGAGCTCCA-3’
F 5’- GAGAGGTAGTCCTCCCCAGG-3’
R 5’- GCTCCACCTCCTTCTCCTCT-3’ 222 208 
D4mgh8 122 106 
D5Rat189 128 135 
D5Rat84 
F 5’- AAACTCCCTTCTTTCTTCCCC-3’
R 5’- TGACCTCTGAATGCACATATCC-3’
F 5’- CATGGGCTCAAGAAATCAAA-3’
R 5’- CCAAAATCCTCAGAGAAGGC-3’
F 5’- TCACAGGTAATGGTAGAAACGTT-3’ 150 131 
D5Rat154 220 218 
D5Rat35 
R 5’- CTATGTGCAAAAACGCATGC-3’
F 5’- CCAACTGCGATCCCTTTAAA-3’
R 5’- CAACTGTCTCCAACTTCGCA-3’
F 5’- CAGCCAGAGAAAAAGCCAAG-3’
R 5’- GTGTGGGAGGGACTGAGAGA-3’ 172 176 
D6Rat108 F 5’- GGCAATATTCAATGAATCAACTTG-3’ 141 150 
D6Rat145 
R 5’- CCAACCCGTCTTTTACCTGA-3’
F 5’- GTGGAGGATGCACAAACAGA-3’
R 5’- ATCCTGAAGTGCCAGGCTAA-3’ 218 220 
D6Rat132 F 5’- CCTCAAAAGGAGAGGTGTCAG-3’ 205 215 
D6Rat121 130 142 
D6Rat79 215 225 
D7Rat35 
R 5’- GCCTGCTGTTTTGGAAGAAC-3’
F 5’- CACATGTCTGTGCAACCCTC-3’
R 5’- GAGGATGTCCTTTGCTTTGC-3’
F 5’- CCCTACACACCTCTTTGGGA-3’
R 5’- CGTAATCTCAAGGCTCACCC-3’
F 5’- TCTTCCCACCAATCCTTTTG-3’ 150 127 
D7Rat103 210 202 
D7Rat141 134 119 
D7Rat128 264 250 
D7Rat117 130 106 
D8Rat77 
R 5’- CCCTATGTTCATTCAAGTAGCCC-3’
F 5’- CTGGTGCTTTTGGGTCTGTT-3’
R 5’- GTGTCAAACTGTGGGGATCC-3’
F 5’- TCCACCCTTAGAAAGCACAGA-3’
R 5’- CTGCTTTTCTGGGAGACTGG-3’
F 5’- GCTTCTGGGGCACCTATACT-3’
R 5’- TTAAGGCCCTTGCAGATTT-3’
F 5’- CAGTTGGCACACTGCTTGTT-3’
R 5’- TTCTGTGCCCTTTAACACCC-3’
F 5’- TGCAGATTATTGAGGTAGCATTG-3’ 216 200 
D8Rat164 
R 5’- ACCTGTGCGTAATCACACCT-3’
F 5’- GAGGTATCCAAGGCAGTGGA-3’
R 5’- CGTTATGCTGCCCAGGATAG-3’ 178 176 
D8Rat156 F 5’- AACCATTCGTCGCACACAC-3’R 5’- ACATTCAAAACAGTCCATTCTTTAT-3’ 200 190 D
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D8Rat205 F 5’- CATGTAGGAACTTTCTATCACCCA-3’ 222 230 R 5’- TGTGTATCTCTGTCTGTCTCTGTTG-3’
D8mgh1 F 5’- TTGTCTGTAAGTATGCACATGTGG-3’ 113 109 R 5’- GATGAGCAGGGGCATGTC-3’
D8Rat71 F 5’- TAGGGACTGCCTGTGTAGGG -3’ 244 242 R 5’- GGCTTTAGTGGGTGGACAAA-3’
D9Rat135 F 5’- GCCACGTCATCATGACAAAC-3’ 141 128 R 5’- TCCGGTCACATGATTTCTGA-3’
D9Rat26 F 5’- AACCTGCAGACAAGCACCTC-3’ 145 141 R 5’- ACTCGTGACCAAAGTCCCAG-3’
D9Rat1 F 5’- GATCTCACAAACATGCACGC-3’ 146 135 R 5’- AACTGTGGGTCAGAAATTCTGTT-3’
D10Rat45 F 5’- TTCCTGGAACAGTGGGAAAC-3’ 116 128 R 5’- TTGCATACACATAGAAACATGCA-3’
D10mgh6 F 5’- CCTGCCTAAGTAATACAGTGGTC-3’ 145 139 R 5’- CCAGACCTTGTATGCTGGGT-3’
D11mit1 F 5’- GACACAGACATACATGCACAACA-3’ 139 123 R 5’- AATGAAAAAGGAAACAGAGTCTGG-3’
D11Rat37 F 5’- GGCATAAGGCCAAGCACATA-3’ 154 164 R 5’- TTTTATCCTGCCTTAGGAGATACAT-3’
D13Rat88 F 5’- AGCAAGGTGTGAAGCCTGAT-3’ 212 234 R 5’- TACAGCAAAAGGGGTTGAGG-3’
D13Rat32 F 5’- CATGCCTCACCTCCAACAC-3’ 134 110 R 5’- TGGTACAATCTACTCGAGCAGG-3’
D14Rat55 F 5’- CACAAATTTCAACCTTGGGC-3’ 222 232 R 5’- GCAAAATTTTGATGGGTTTG-3’
D15Rat123 F 5’- CCCCTACATCCATGGCATAC-3’ 126 130 R 5’- TTCCCCCTCTTGTTCTTCCT-3’
D15Rat106 F 5’- AAACCTGTGGTCTCTACACACAG-3’ 221 185 R 5’- GCCACTACCCCAATTGGACT-3’
D17Rat12 F 5’- GCCTTCATTAGAAAGTGAAAGTAAA-3’ 182 161 R 5’- GGCAAAAGGACAGAGGATGA-3’
D17Rat79 F 5’- ACAGGTGCTTCTGCCTAGGA-3’ 190 204 R 5’- TCCAAAATATGCCTTTCTAAACAA-3’
D17Rat52 F 5’- GGCGGTGGAAATTGATTAAA-3’ 178 157 R 5’- TGTCTGCGATTGTACGTGTG-3’
D18Rat48 F 5’- CTGGCCTTCATGATGTCTACA-3’ 154 150 R 5’- GCCCAGAATGAAGTTTATTCATTT-3’
D18Rat61 F 5’- TCCCAGTGTTTGCTAGACCA-3’ 264 238 R 5’- AATCAAGAGGCTGGGACTGA-3’
D18Rat76 F 5’- TTGTTTCCAATGTGGTATGGA-3’ 124 120 R 5’- CCCTGTCACCCTGTCTCTGT-3’
D19mit7 F 5’- AGGGCTTTGCTGAATGCTTA-3’ 119 113 R 5’- AGAGTGGTGGTGAAAGTGGG-3’
D20Rat46 F 5’- GGCAAAACACCAATGCCTAT-3’ 150 170 R 5’- AAGTACTGAGTGGGCTGCGT-3’
D20Rat70 F 5’- TCATGTAGTTTTGTCTACACTGCTT-3’ 184 194 R 5’- CCGGTCATTGAAGTTAGCCA-3’
D20Rat29 F 5’- GAGGCTCCAGGACTCAACAG-3’R 5’- CCTTCCATAGACCTATAGCGGA-3’ 231 241 
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D12Rat1 F 5’-TGGGTGGATTCTTGAGGATC-3’R 5’-GCTAGTCCAGGGATGCTGAC-3’ 6FAM 128 131 
D12Rat63 F 5’-TTCTTCCACTGTCTCCGCTT-3’ NED 179 166 R 5’-TGAGGCTTCAGAGGGACTGT-3’
D12rat43 F 5’-TCCCACAAGTTCTCTGTGCA-3’ NED 321 241 R 5’-CTCACTATGGCCTGGACCTT-3’
D12Mgh1 F 5’-ACACATGCAACCACGCAC-3’ 6FAM 136 140 R 5’-CCCCAGTTCTGGTGACAATT-3’
D12Mgh2 F 5’-TGCCATGGTACACATGCAC-3’ 6FAM 157 149 R 5’-CCCTGATAGGAATACCTTTTTCA-3’
D16Mit2 F 5’-AACGAGGGGAAATAAGCACC-3’ 6FAM 169 163 R 5’-ATCCAAACCTGACATCTGGC-3’
D16Mgh3 F 5’-GCCACTCTGGGGTGATTTTA-3’ 6FAM 227 215 R 5’-AACCCCAGAACCTGAGAGGT-3’
D16Mgh1 F 5’-GACCTCCAGGATTGGTGAGA-3’ NED 240 233 R 5’-ACAACCCATGAGGCAGACAG-3’
D16Rat67 F 5’-TGTCACTTACCTGTGGCAGC-3’ 6FAM 232 253 R 5’-GGCATAAGATGAGGCTAACGA-3’
D16Rat60 F 5’-TGAATTTTGAAAGGAAAGGCA-3’ NED 137 139 R 5’-CTCGAGTTTGGGGAAATGAA-3’
D16Rat15 F 5’-ATCGGTAAACAAATCGCTGG-3’R 5’-TGGCATCTTTCGCTTAGACA-3’ NED 151 143 
Table S3. Microsatellite markers and their primers used for genotyping 
SHR.W4, SHR.W12 and SHR.W16 
Marker Primer sequence Label 
SHR 
(bp) 
WKY 
(bp) 
D4Rat143 F 5’-TATGGAGGGACCCCTACTCC-3’ NED 120 126 R 5’-GGACTCTGCCTTCCTCTGAA-3’
D4Rat10 F 5’-TGCATTAGTCAGGGGTACAAA-3’ NED 171 169 R 5’-AACTCTGCCTCTGGACGAAA-3’
D4Rat126 F 5’-CATTCCTGTGCCACTCAAGA-3’ 6FAM 123 131 R 5’-GCAGGTAAGAAAAGCAAGGC-3’
D12Rat89 F 5’-GCAGTGAGAGACAGATGTGCA-3’R 5’-CCTTGAAATTGGTTCTTGGC-3’ NED 148 142 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Disease Models & Mechanisms 10: doi:10.1242/dmm.026716: Supplementary information 
Usp42 12:14,904,019-
14,922,553:1 
Adrenal: 
Serum 
cysteinylglycine 
0.66 0.0004 
- 
Hspb1 12:25,837,084-
25,838,661:-1 
Liver: 
Fat cell volume. -0.74 2.3x10-5 
skeletal 
muscle 
Pdgfrl 16:54,098,419 - 
54,161,461:-1 
Left ventricle: 
Delta captopril 
effects 
-0.60 0.0009 
heart 
QTT, quantitative trait transcript; eQTL, expression quantitative trait locus. 
*data from Langley et al 2013.
Table S4. Chromosome 12 and 16 candidate gene QTT phenotypes and 
eQTL status  
Gene Chromosome QTT description R2* P-value* Reported
cis-eQTL 
tissue* 
Zkscan5 12:13,224,021-
13,245,216:-1 
Kidney: 
Systolic blood 
pressure mm Hg 
0.58 0.0008 
adrenal, 
aorta, 
heart, fat, 
kidney, 
liver, 
skeletal 
muscle 
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Table S5. Human GWAS genes for cardio-metabolic traits located in congenic regions on rat chromosome 12 and 16 
Associated 
gene 
Disease/trait Strongest GWAS SNPs Human gene 
location 
(GRCh38.p5) 
Rat gene 
location 
(Rnor_5.0) 
Chromosome 12 congenic region 
FRY rs95333282 13:32,031,300 –
13:32,299,122 
12:7,565,891 –
12:7,925,464 
INSR 
Blood pressure (smoking 
interaction) 
Insulin resistance rs1799816 19:7,112,255 –
19:7,294,034 
12:3,848,670 –
12:3,989,302 
PDX1 Type 2 diabetes 13:27,920,020 –
13:27,926,231 
12: 11,609,488 –
12:11,614,655 
RNF6 Type 2 diabetes 
rs137852783, rs137852784 
rs137852785, rs137852786 
rs10507349 13:26,132,115 –
13:26,222,493 
12:12,676,145 –
12,685,173 
SLC12A9 rs7801190 7:100,826,820 –
7:100,867,009 
12:24,499,476 –
12:24,465,924 
MLXIPL 
Hypertension, type 2 
diabetes 
Metabolic syndrome rs13226650 7:73,593,194 –
7:73,624,543 
12:26,588,200 –
12:26,620779 
Chromosome 16 congenic region 
CACNA1D rs10452033, rs9810888, 3:53,494,65 –
rs1401492 3:53,813,733 
16:6,044,524 –
16:6,339,170 
GRID1 
Electrocardiographic 
traits 
Systolic blood pressure 
Insulin 
resistance/response 
LV wall thickness rs7910620 10:85,599,555 –
10:86,366,493 
16:9,495,903 –
16:12,273,26 
NRG3 Cardiac hypertrophy rs1484170 10:81,875,298 –
10:82,989,979 
16:15,661,430 –
16:16,817,319 
LPL Metabolic syndrome 8:19,901,717 –
8:19,967,258 
16:22,431,494 –
16:22,455,871 
MARCH1 Type 2 diabetes 
rs268, rs295, rs301, 
rs2197089, rs10096633, 
rs7841189, rs2083637, 
rs1441756 
rs3792615 4:163,524,298 –
4:164,384,050 
16:24,882,375 –
16:25,407,999 
MSMO1 Insulin-related traits rs17046216 4:165,327,623 –
4:165,343,160 
16:26,738,367 –
16:26,754,806 
KLKB1 Metabolic traits rs4253252 4:186,208,979 –
4:186,258,471 
16:49,875,019 –
16:49,898,363 
PPP1R3B rs48411132 8:9,136,255 –
8:9,151,574 
16:60,089,267 –
16:60,101,512 
KCNU1 rs2407103 8:36,784,324 –
8:36,936,128 
16:70,577,547 –
16:70,663,252 
ZMAT4 
Fasting insulin/glucose 
related traits (interaction 
with BMI) 
Insulin 
resistance/response 
Fasting plasma glucose rs2722425 8:40,530,590 –
8:40,897,883 
16:72,402,519 –
16:72,450,584 
ANK1 Type 2 diabetes rs516946, rs515071 8:41,653,220 –
8:41,896,762 
16:73,314,002 –
16:73,459,822 
CSMD1 rs2627282, rs2407314 8:2,935,353 –
8:4,994,972 
16:76,755,073 –
16:78,434,380 
ARHGEF7 
Blood pressure 
measurement (sodium 
intervention) 
Insulin 
resistance/response 
Homeostasis model 
assessment of insulin 
resistance (interaction) 
rs12853515 13:111,114,559 –
13:111,305,737 
16: 82,479,277 –
16:82,605,606 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
